Valuation: Axsome Therapeutics, Inc.

Capitalization 5.13B 4.96B 4.66B 4.13B 7.34B 449B 8.18B 56.04B 20.82B 184B 19.22B 18.83B 775B P/E ratio 2024 *
-19.5x
P/E ratio 2025 * -49.6x
Enterprise value 5.04B 4.87B 4.58B 4.06B 7.21B 442B 8.04B 55.05B 20.46B 181B 18.88B 18.5B 761B EV / Sales 2024 *
13.1x
EV / Sales 2025 * 7.66x
Free-Float
81.71%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart

Last Transcript: Axsome Therapeutics, Inc.

1 day-3.42%
1 week-0.66%
Current month-0.66%
1 month+26.24%
3 months+16.60%
6 months+26.13%
Current year+25.00%
More quotes
1 week
103.98
Extreme 103.98
114.06
1 month
79.19
Extreme 79.19
114.06
Current year
79.19
Extreme 79.19
114.06
1 year
64.11
Extreme 64.11
114.06
3 years
20.63
Extreme 20.63
114.06
5 years
19.38
Extreme 19.38
114.06
10 years
1.94
Extreme 1.94
114.06
More quotes
Director TitleAgeSince
Chief Executive Officer 56 2012-01-11
Director of Finance/CFO 50 2018-05-15
Chief Operating Officer 41 2014-03-31
Manager TitleAgeSince
Chairman 56 2012-01-11
Director/Board Member 63 2014-11-30
Director/Board Member 57 2014-11-30
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-3.42%-0.66%+12.49%+246.53% 5.13B
-1.10%-3.77%-11.51%+5.99% 81.84B
+6.52%+16.00%+40.44%+52.03% 56.82B
+1.67%+0.56%+111.83%+112.78% 37.13B
-0.72%-1.79%-41.24%-36.13% 20.6B
-0.13%+5.38%+410.43%+867.66% 14.36B
-1.09%-0.04%+29.28%+1.06% 14.28B
-0.09%-0.06%+85.23%+149.19% 13.49B
-0.64%+0.90%-28.70%-28.47% 12.18B
-0.22%-0.34%+10.40%-43.05% 11.78B
Average +0.08%+1.27%+61.86%+132.76% 26.76B
Weighted average by Cap. +1.05%+0.71%+44.68%+81.41%
See all sector performances

Financials

2024 *2025 *
Net sales 386M 373M 351M 311M 552M 33.81B 616M 4.22B 1.57B 13.87B 1.45B 1.42B 58.29B 637M 616M 579M 514M 912M 55.86B 1.02B 6.97B 2.59B 22.92B 2.39B 2.34B 96.33B
Net income -260M -252M -237M -210M -372M -22.81B -415M -2.84B -1.06B -9.36B -975M -955M -39.33B -112M -109M -102M -90.53M -161M -9.85B -179M -1.23B -456M -4.04B -421M -412M -16.98B
Net Debt -89.86M -86.9M -81.71M -72.46M -129M -7.88B -143M -983M -365M -3.23B -337M -330M -13.59B -247M -239M -225M -200M -354M -21.7B -395M -2.71B -1.01B -8.9B -928M -909M -37.42B
More financial data * Estimated data
Logo Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Employees
607
Calendar
More about the company
Date Price Change Volume
25-02-07 105.76 $ -3.42% 868,718
25-02-06 109.50 $ -3.95% 717,224
25-02-05 114.00 $ +0.96% 866,571
25-02-04 112.92 $ +5.11% 825,624
25-02-03 107.43 $ +0.91% 966,048

Delayed Quote Nasdaq, February 07, 2025 at 04:00 pm EST

More quotes
Trading Rating
Investor Rating
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
105.76USD
Average target price
137.38USD
Spread / Average Target
+29.89%
Consensus

Quarterly revenue - Rate of surprise